Gel formulations for guiding radiotherapy

Thomas Lars Andresen; Rasmus Irming Jølck; Morten Albrechtsen

Gel formulations for guiding radiotherapy

Thomas Lars Andresen (Inventor)
, Rasmus Irming Jølck (Inventor)
, Morten Albrechtsen (Inventor)

Department of Health Technology

Research output: Patent

121 Downloads (Orbit)

Abstract

The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

Original language	English
IPC	A61K 49/ 04 A I
Patent number	EP3003397
Filing date	24/05/2013
Country/Territory	Denmark
Priority date	23/05/2014
Priority number	WO2014EP60673
Publication status	Published - 13 Apr 2016

Bibliographical note

Also published as: AU2014270358A1; AU2014270358B2; BR112015029144A2; CA2913100A1; CN105407927A; CN105407927B; EP3003397A1; WO2014187962A1; HK1223545A1; IL242676A; JP2016519154A; JP6537498B2; KR20160032008A; MX2015016155A; RU2015154681A; RU2703303C2; US2016089454A1; US10561746B2

Access to Document

FulltextFinal published version, 2.08 MB

OpenUrl availability

Full text

Cite this

@misc{079d77d1a3fc44aa95ff9009e5adfc21,

title = "Gel formulations for guiding radiotherapy",

abstract = "The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60\% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body. ",

author = "Andresen, \{Thomas Lars\} and J{\o}lck, \{Rasmus Irming\} and Morten Albrechtsen",

note = "Also published as: AU2014270358A1; AU2014270358B2; BR112015029144A2; CA2913100A1; CN105407927A; CN105407927B; EP3003397A1; WO2014187962A1; HK1223545A1; IL242676A; JP2016519154A; JP6537498B2; KR20160032008A; MX2015016155A; RU2015154681A; RU2703303C2; US2016089454A1; US10561746B2 ; EP3003397; A61K 49/ 04 A I",

year = "2016",

month = apr,

day = "13",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Gel formulations for guiding radiotherapy

AU - Andresen, Thomas Lars

AU - Jølck, Rasmus Irming

AU - Albrechtsen, Morten

N1 - Also published as: AU2014270358A1; AU2014270358B2; BR112015029144A2; CA2913100A1; CN105407927A; CN105407927B; EP3003397A1; WO2014187962A1; HK1223545A1; IL242676A; JP2016519154A; JP6537498B2; KR20160032008A; MX2015016155A; RU2015154681A; RU2703303C2; US2016089454A1; US10561746B2

PY - 2016/4/13

Y1 - 2016/4/13

N2 - The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

AB - The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

M3 - Patent

M1 - EP3003397

Y2 - 2013/05/24

ER -

Gel formulations for guiding radiotherapy

Abstract

Bibliographical note

Access to Document

OpenUrl availability

Fingerprint

Cite this